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Abstract  
Since the beginning of the twentieth century, there have been attempts at creating artificial hair to treat baldness. 
Major evolution took place at the end of 1970’s when, unfortunately, artificial hair treatments were applied without 
appropriate medical controls, resulting in sub-standard results from the use of unsuitable materials and technique. 
The large improper use of this technique in North America from no medical personnel and with dangerous fibres 
led the Food and Drug Administration (FDA) to suspend the procedure in 1983. In Europe, a new trial on artificial 
hair procedure started at the beginning of 1990’s. 
In 1995 the European Union (UE) recognised the artificial hair implant as a legitimate medical treatment and 
outlined the rules related to that procedure. In 1996, biocompatible fibres (Biofibre®) produced by Medicap® Italy 
were approved by the UE Authorities and by the Australian Therapeutic Goods Administration (TGA) as medical 
devices for hair implant. An effective medical protocol was developed during the following years to provide correct 
guidelines for appropriate treatment, and to reduce possible related complications. Automatic Biofibre® hair 
implant represents the last achievement in this hair restoration technique with significant advantages for the 
patients. 
 
 
 
 
 
Introduction 
 
The very first experiences with artificial hair 
implants date back to the beginning of the 
twentieth- century as recorded by a USA patent [1].
 
In 1930 Dr. M. Sasagawa reported his experiments 
with the implantation of cut human hair [2]. 
Nonetheless, its greatest evolution did not take place 
until the 1970’s. In 1976, Dr S. Yamada and Dr. K. 
Fukuta presented their technique to JMJ [3]. From 
1976 fierce competition within the North American 
market resulted in a number of different companies 
offering inadequately tested fibers for human hair 
replacement with very negative results [4][5][6]. In 
those years, the technique was often being performed 
inappropriately by non-medical operators, in non-
medical environments and without any medical 
protocol. That led to frequent complications (severe 
infection, inflammation, broken hair embedded in the 
scalp, etc,) resulting from unsuitable materials and 
techniques. In the USA, the above situation 
provoked a Government inquiry followed, in 1983, by 
a ban on the implantation with special reference to 
the materials utilized at that time as human hair and 
colored industrial fibers such as polyester, modacrylic 
and polyacrylic fibers (FDA, June 13, 1983) [7]. 
During the following years, some European 
companies specialized in the bio-medical field 
started researching on artificial hair in cooperation 
with University Departments. In 1993 biocompatible 
fibers (Biofibre®) were developed in Italy by Medicap 
company. From 1993 onward clinical trials [8][9][10] 
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and histological studies [11][12]
 
were performed with 
encouraging results, leading to additional research on 
the biocompatible material field and medical 
protocol application. In 1995 the UE recognized the 
artificial hair implant technique as a medical act, 
setting that strict and ethical medical protocols must 
be followed to ensure the safety of implants and 
minimize complications [13]. In consequence of this 
regulation, all fibers to be used for this practice have 
to be compulsory approved and certified as CE 
medical devices. The approval of this methodology 
was a great advantage for patients since it legally 
prevented the procedure from being performed by 
unqualified people. From the beginning of the 
2000’s many cases of patients treated by artificial hair 
implant were worldwide presented to the scientific 
community [14][15][16][17], getting favorable 
outcome and interest also for USA doctors. On 
2007, a study about the use of Biofibre® hair 
implant to treat scalp scars was published [18]
 
as 
an additional indication for this technique. In 2011, 
Biofibre® hair implant was included in an academic 
text of cosmetic dermatology [19] at the World 
Congress of Cosmetic Dermatology (WCOCD). In 
2013, the first Automatic machine for Biofibre® hair 
implant was presented by Medicap Italy with 
significant advantages for the technique [20]. In 
2014 was released the new high-density version of 
Biofibre®, named as MHD® hair, which allows triple 
hair quantity with the same number of implants. 
Such fibres are presently used for the crown area 
only allowing very mild aftercare and the very quick 
result, while for the front hairline the single Biofibre® 
is recommended to ensure a more natural aesthetic 
result. Recent PubMed publications bring additional 
evidence of the reliability of the present artificial hair 
implant technique [21].  
 
 
Materials 
 
The safety of implant fibres has to be 
assured. At the same time, good aesthetic quality and 
durability must also be considered to maintain the 
expected results over time. The main features 
required are biocompatibility, resistance to traction, 
the absence of capillarity, resistance to physical-
chemical stress, low tissue trauma, and good 
aesthetic qualities. Biofibre® medical hair prosthetic 
fibres meet all the biocompatibility and safety 
requirements established by international standards 
committees for medical devices. They are available 
in 13 colours (Fig.1), with different lengths (15, 30 or 
45 centimetres) and in various shapes (straight, wavy, 
curly and afro) to satisfy different patients requests. 
Presently, they are also available in the new high-
density version, MHD®, which allows for each implant 
to have three hairs implanted as the final result. 
This fibre is used for the crown area only, while for 
the front hairline the single Biofibre® is 
recommended. The instruments used for the 
procedure are also very important. The special 
hooked needles are less traumatic according to 
diameter and shape. These instruments also ensure 
easy work for the physician and best comfort for the 
patient. Automatic Biofibre® hair implant device 
represents a valuable solution to encounter such 
requirement. 
 
Figure 1: Biofibre® is available in 13 colours, with different lengths 
(15, 30 or 45 cm) and in various shapes (straight, wavy, curly and 
afro) 
 
 
Indications 
 
Biofibre® hair implant is carried out thanks 
to minor surgery. It is indicated for diffuse alopecia 
or hair thinning both for male and female patients 
(Fig. 2a-be Fig. 3a-d).  
a)
 
b)
 
Figure 2: a):  Patient with androgenetic alopecia; b): Final results 
after five implant sessions with 4000 Biofibre® as a whole 
 
This technique ensures an immediate 
aesthetic result and sufficient quantity of hair in a 
short time without requiring any donor area. It is a 
very soft surgery not requiring hospitalisation and 
can be used alone or in combination with other hair 
restoration techniques to improve final aesthetic 
results when required [15][17]
 
or in case of the poor 
donor area. It is also performed to correct scars or 
scalp burns (Fig. 4a-b). This technique is not 
indicated for implant on the temples, on low frontal 
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hairline, scalp areas with very thin dermal tissue (such 
as the sideburns) or in case of the pathologically 
atrophic scalp. 
 
Figure 3: A 53 years old woman with chronic telogen effluvium 
(upper left); Final results after three implant sessions with 2000 
Biofibre® as a whole (upper right, down) 
 
 
Patient’s selection 
 
It is important that patients are previously 
selected and well informed about the correct aftercare 
protocols and the pros and cons of this procedure. 
Biofibre® hair implant is not indicated in patients with 
diabetes mellitus, hepatitis A, B and C, autoimmune 
diseases, chronic scalp diseases, severe psychosis, 
not stabilised alopecia areata, when there is lack of 
personal hygiene, or with employment in dusty or 
dirty environments. A preliminary screening of the 
patient, including blood testing, is essential before 
proceeding with an implanted test. Blood tests list 
include: Complete blood count, Urea, Creatinine, 
Bilirubin (total and direct), Gamma-Glutamyl 
Transferase (GGT), Alanine aminotransferase (ALT), 
Aspartate aminotransferase (AST), Fibrinogen, 
Treponema Pallidum Haemagglutination (TPH), Anti-
HIV, Hepatitis A-B and C Markers/Hbsag, Erythrocyte 
Sedimentation Rate (ESR), Venereal Disease 
Research Laboratory (VDRL), Prothrombin Time (PT), 
Partial Thromboplastin Time (PTT), C Reactive 
Protein, Fasting Blood Sugar Levels, Serum protein 
electrophoresis, Urinalysis, and Electrocardiogram. 
Before proceeding with implant sessions, a small 
number of implant tests must be performed. 
 
Figure 4:  Patient with two frontal scars (upper); Final result after 
two implant sessions with 1500 Biofibre® as a whole (down) 
 
They should be observed every one week 
over a period of at least one month. If not significant 
problems are observed, larger sessions can be 
performed at intervals of 1 month each. 
 
 
Implant Technique and Medical Protocol: 
From the Stone Age To Now 
 
A correct hair implant procedure requires a 
combination of safe fibres, suitable implant 
instruments, trained doctors, careful patient 
selection, and proper after-care follow-up. 
Selection of a suitable patient is important. A 
preliminary visit with tolerance testing allows the 
exclusion not only of those patients who are not 
suitable for the fibres implants but also those who 
have contraindicating skin conditions. Patient must 
avoid smoking, drinking alcohol for two days before 
implant, and taking salicylic acid for at least three 
days before surgery. Before starting the implant, the 
implant area must be carefully disinfected. The 
tolerance implant test is performed with 100 fibres 
and results are evaluated weekly and after four 
weeks. The implant technique is based on small 
hooking needles that go out the implanter and hook 
the Biofibre® root (reversible knot®), placing it under 
the scalp at galea level. In this way, the root can be 
held by the fibrous tissue and avoid premature hair 
loss. The implanter performed by automatic machine 
allows reaching always the right deepness (Fig. 5). 
The procedure is performed under local anaesthesia 
and in one hour up to 600 Biofibre® are usually 
implanted. A small quantity of local anaesthesia is 
recommended initially, with repeated administration in 
case of need. The local anaesthesia commonly used 
is carbocaine or lidocaine 2% with adrenaline 
1:100.000. The suggested quantity of anaesthesia is 
1 cc per 200 Biofibre®. The average implant is 
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about 1000 Biofibre® per session, respecting the 
appropriate distance between each fiber.  
 
Figure 5: Right implant deepness of Biofibre® performed by 
automatic machine to allow best retention rate 
 
The implantation is performed to grant the 
appropriate directional orientation of the fibres to 
avoid unwished traction and to enhance the final 
appropriate aesthetic result. Implants performed by 
the automatic machine minimise implant trauma and 
hastens cicatrization of the implanted area by 
allowing a higher degree of fixation, thereby allowing 
a quicker, better aesthetic result. At the end of the 
implant procedure, the scalp is disinfected with 
betadine solution. For large implant sessions, an ice 
pack protected by sterile gauze is applied for 5 
minutes on the scalp. Then the fibres are finally 
combed with a large toothcomb, holding them at the 
base to prevent surfacing and the risk of premature 
fall. The first cleaning with ketoconazole shampoo is 
suggested after three days. Systemic antibiotic 
coverage is recommended for one week after the 
implant, allowing adjustments in therapy depend upon 
local circumstances and patient's medical history. The 
patient must avoid sports, sauna and other activity 
that can increase sweating for the first three weeks 
until cicatrisation takes place. Also, should avoid 
smoking and drinking alcohol for one week after 
implant session. Before proceeding with the following 
implant sessions, a four week of pause has to be 
respected. 
 
 
Follow Up / After Care Protocol 
 
Maintenance of scalp hygiene and periodic 
medical check-ups are required to keep the expected 
aesthetic results. Follow-up is very important to check 
the patient’s scalp conditions and prevent possible 
complications such as infection or inflammation. 
Biofibre® after-care protocol consists of regular follow 
up, proper scalp hygiene, use of suitable products, 
and avoidance of dangerous products or treatments 
such as hair bleaching, permanent waving, thermal 
shocks, and hair curlers. Various behaviours that can 
lead to side effects with the implant procedure include 
lack of patient hygiene or lack of asepsis during the 
procedure, excessive density or quantity of 
implanted fibres in one session, a traumatic implant 
procedure, personal fibre intolerance, incorrect 
choice of implant area, and failure in after-care 
procedures. Most of these problems can be solved 
with appropriate therapies and change of habits. 
When the problem is recurrent or cannot be easily 
resolved with appropriate antibiotics and/or 
corticosteroid therapy, it may be necessary to 
proceed with fibre removal. The reversible knot of 
Biofibre® does not allow the fibre to fall out from the 
implant area, but allow it to be pulled out entirely with 
appropriate traction with no remains (Fig. 6).  
 
Figure 6: a Reversible knot of Biofibre®  after extraction. No 
remains stay embedded on the scalp, allowing prompt restitution 
ad integrum of scalp 
 
This ability to remove the implant contributes 
to the overall safety of the procedure since once 
removed; the scalp is healed after several days 
without scars [14]. Special attention has to be 
reserved to the scalp sebum. 
Sebum is an important and useful natural 
shield for the scalp, but when it is in excess, it 
must be removed before it leads to sebum 
accumulation around implanted fibres that can cause 
early fibre loss and may predispose the patient to a 
scalp infection. Sebum accumulation can be avoided 
by gently massaging the scalp with a soft 
toothbrush during the shower once every two 
weeks according to the patient scalp, or they can be 
easily removed periodically with forceps extraction at 
the implant clinic. After that, the scalp must be 
cleansed with an antiseptic spray (e.g. chlorhexidine). 
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Clinical and Histological Studies 
 
The implant technique was validated with 
clinical studies and scientific research from the 1990’s 
onwards [8][9][10][18][21]. Differences in the results 
achieved during these years represent a constant 
improvement of the technique and related protocols. 
A recent clinical study about hair implant conducted 
on 133 patients (95 men and 38 women) for three 
years has shown very satisfactory results (Fig. 7a-
7c).  
a)  
b)  
c)  
Figure 7: a): clinical features of the patients; b): technique 
information; c): efficacy and tolerability of implants 
The most represented age group of this 
study was between 30 and 60. These patients 
underwent implants of up to 6000 Biofibre® (average 
of 5-6 implants in three months). Fiber loss was not 
more than 10% per year in 91.4% of the cases, 15% 
to 7.8% of the cases, and 20% in 0.8% of the cases. 
96.2% of the patients stated that they were satisfied 
with the results of the implant, while 3.8% were not 
satisfied. As for post-implantation tolerance and 
complications, 90.3% of the patients recorded no 
difficulties after surgery. Of the remainder, 5.9% 
developed mild infections and 3.8% presented with 
inflammatory changes, mainly from the use of 
inappropriate chemical substances. Resolution of the 
scalp infectious and inflammatory issues occurred in 
an average of 15 days with the use of systemic 
antibiotics and/or local corticosteroid therapy. In 2.1% 
of the cases (3 patients), it was necessary to remove 
the fibres, which was accomplished without leaving 
any lasting scars. 
Histological studies after three years 
[11][12][21]
 
on Biofibre® (Fig. 8a-8d) have shown 
that each fibre appears surrounded by a fibrous 
layer, hindering bacterial penetration. Thin diameters 
and proper distances between the fibres reduced the 
occurrence of rejection phenomena. 
Histopathologically, a sort of infundibulum comprised 
of Malpighian epithelium, similar to the cutaneous 
one, formed around the implanted fibre. We can 
consider it as the basis for adequate fibre anchorage. 
A moderate, controlled inflammatory infiltrate was 
noticed. In the middle and deep reticular dermis, the 
fibre is in contact with collagen. In the hypodermis, no 
inflammatory infiltrate was noticed. 
  
  
Figure 8: Within the pseudo-infundibula, a compact keratin 
layer adheres closely to the fibres. In the middle and deep 
reticular dermis,  the fibres are surrounded by a small amount of 
focally granulomatous chronic infiltrate.  In the deepest dermis 
and hypodermis, the fibres are surrounded by fibroplasia, and 
no inflammatory infiltrate is noted. (Courtesy of Dr PA Fanti, Lab 
of Dermatology Histopathology, University of Bologna, Italy) 
 
 
Discussion 
The problem of alopecia affects both sexes 
and all ages. Between the main surgical techniques 
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for solving the problem of common baldness, the 
implant of biocompatible fibres Biofibre® has to be 
listed. This is a non-traumatic technique, which is 
performed under local anaesthesia and enables the 
implantation of the desired quantity of hair, the 
immediate excellent aesthetic result with a natural 
appearance, and the accompanying psychological 
and physical rebound. Artificial hair will not age – i.e. 
it will not turn white. Biofibre® hair implant is indicated 
to cover thinned and/or bald areas in case of 
irreversible alopecia. It is also very successful in 
alopecia of cicatricial origin (scars, burns). Emerging 
studies are proving its efficacy in case of total 
alopecia areata. Post-operative patients are advised 
to avoid hair dyes with ammonia, hair bleaching, 
permanent waving, excessive heat, hair curler and 
thermal shocks, and violent brushing. The 
disadvantages of this technique are that the 
implanted “hair” will not grow. It needs some 
periodical re-touches to keep the expected aesthetic 
result. Patients with unbalanced diabetes, hepatitis, 
autoimmune diseases, chronic scalp diseases, or 
unstable forms of alopecia areata are not suitable for 
this technique. Implant in some scalp areas must be 
avoided: temples, the low front line on the forehead, 
and over very thin or atrophic scalp. Spontaneous 
Biofibre® hair implants loss is very subjective as it is 
influenced by many factors such as the patient’s scalp 
and habits, the climate and the implant procedure. 
The use of automatic Biofibre® hair implant devices 
reduces the average implant loss since they allow to 
place the fibres always in the right depth and angle 
orientation. 
Local infections are mostly due to poor hygiene of the 
patient and lack of the after-care protocol. Local 
inflammation is normally caused by the use of the 
patients of improper products. Fiber extractions 
although very rare, allow a prompt solution of the 
problem without remains. 
Pre-operative patient selection, mutual consent of 
patient, appropriate implant equipment, asepsis of 
the operation field, preparation of the patient, correct 
implant techniques and medical protocols, 
compatibility tests, implant on suitable implant 
areas, patient records, post-operative treatment and 
drug prescription, aftercare patient instructions 
providing forbidden products and a treatments list, 
periodical check-ups and post-implant management 
must be followed. 
 In conclusion, why Synthetic Hair Implant is 
approved in many Countries and not in some others is 
still mysterious. We tried here to provide the main 
technical changes, which made this technique safe 
and effective. Biofibre® Hair Implant is a soft surgery 
technique, performed under local anaesthesia by a 
manual implanter or by an automatic machine with 
certified medical fibres. This technique allows 
immediate aesthetic result, without patient downtime 
and with relevant psychological comfort for the 
patient. It can be considered an efficient hair 
restoration technique for male and female patients 
in cases of androgenetic alopecia, hair thinning and 
scars. Conditions for the success of the implant 
are suitable patient selection, healthy scalp, 
compliance with the implant and post-implant 
medical protocol, correct patient after-care and 
periodical medical check-up. Clinical and histological 
studies demonstrated that Biofibre® hair Implant is 
safe and well tolerated by patients, and can be 
totally reverse if needed. It can be used alone or in 
combination with other hair restoration techniques. 
Studies about implant on total alopecia areata are 
successfully taking place.  
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